Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Reference Treatment- BMS-986165-01
BMS-986165-01 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-985165-01 prototype formulation 1 | EXPERIMENTAL | - |
| BMS-986165 Tablet | EXPERIMENTAL | - |
| BMS-985165-01 prototype formulation 2 | EXPERIMENTAL | - |
| BMS-985165-01 prototype formulation 3 | EXPERIMENTAL | - |
| BMS-985165-01 prototype formulation 3 or 4 | EXPERIMENTAL | - |
| BMS-985165-01 prototype formulation 3, 4 or 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986165-01 | DRUG | Participants will receive BMS- 986165 -01 in prototype formulation |
| BMS-986165 Tablet | DRUG | Participants will receive BMS-986165 in tablet form. |
| Famotidine | DRUG | Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Patients must be willing and able to complete all study-specific procedures and visits * Healthy patients, as determined by no clinically significant deviati...
Top 18 of 19 competitors
BMS-986165-01 is an investigational small molecule developed by Bristol-Myers Squibb Company for lupus, an immunology condition. It has been studied in a Phase 1 clinical trial conducted in the United Kingdom. It is also referred to as Reference Treatment- BMS-986165-01 in study documentation.
BMS-986165-01 has been studied for lupus, an autoimmune disease in the immunology therapeutic area. The single completed Phase 1 trial enrolled healthy adult volunteers rather than patients with active lupus, and it was designed to characterize the pharmacokinetic profile of the tablet formulation.
Bristol-Myers Squibb Company, which trades under the ticker BMY, is the developer of BMS-986165-01. The company sponsored the Phase 1 study of the compound in lupus.
BMS-986165-01 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The study was randomized and controlled but not double blind, and it enrolled 33 participants.
BMS-986165-01 has been evaluated in one completed Phase 1 trial, NCT04065932, titled A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets. The trial enrolled 33 healthy volunteers aged 18 years and older in the United Kingdom and included both male and female participants.
Yes. BMS-986165-01 is also known as Reference Treatment- BMS-986165-01. Both names refer to the same investigational small molecule developed by Bristol-Myers Squibb for lupus, so search results under either name describe the same Phase 1 compound.